Celsion Reports Final Clinical, Translational Research Data From OVATION Study At AACR: '100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts'